Oncology Corporate Profile
Verastem, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|duvelisib||P13K inhibitor||Chronic Lymphocytic Leukemia (CLL)||III|
|defactinib||P13K inhibitor||Chronic Lymphocytic Leukemia (CLL)||II|
|defactinib (+ pembrolizumab)||P13K inhibitor||Mesothelioma||II||Merck|
|defactinib (+ pembrolizumab)||P13K inhibitor||Non Small Cell Lung Cancer (NSCLC)||II||Merck|
|duvelisib||P13K inhibitor||Non-Hodgkin's Lymphoma (NHL)||II|
|defactinib (+ avelumab)||P13K inhibitor||Ovarian cancer||II||Pfizer and Merck|
|defactinib (+ pembrolizumab)||P13K inhibitor||Pancreatic cancer||II||Merck|
|defactinib (+ pembrolizumab and gemcitabine)||P13K inhibitor||Pancreatic cancer||I||Merck|
|duvelisib||P13K inhibitor||Refractory T-cell Lymphoma||I|
|VS-4718 (+ abraxane)||FAK/PYK2 inhibitor||Pancreatic cancer||Preclinical|
|VS-4718 (+ abraxane)||FAK/PYK2 inhibitor||Various cancer types||Preclinical|
|VS-5584||mTORC1/2 inhibitor||Various cancer types||Preclinical|
4/3/2017 11:00 am
[Business Wire] - Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4th at 3:00 p.m.
4/3/2017 07:03 am
4/2/2017 06:00 pm
[Business Wire] - Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced the oral presentation of data for its lead focal adhesion kinase inhibitor, defactinib, by the Company’s scientific collaborator David G.
3/29/2017 05:00 pm